IMR Press / JIN / Special Issues / parkinson_and_DBS

Cyto-neurology in Parkinson's Disease Pre-and Post-Deep Brain Stimulation (DBS)

Submission deadline: 31 August 2022
Special Issue Editors
Lilach Soreq, PhD
Institute of Neurology, University College London, Queen Square, London, UK; The Francis Crick Institute, Somers Town, London, UK
Interests: aging; alzheimer’s disease; bioinformatics; deep brain stimulation; statistics; microRNAs; microarrays; parkinson’s disease; RNA-Seq
John Hardy, PhD
Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, UK
Interests: alzheimer’s disease; neurological diseases; parkinson’s disease
Special Issue Information

Dear Colleagues,

Parkinson’s disease (PD) is a devastating late-life disease with increasing prevalence. Tremors occur in 15% of all patients and several other neurological diseases show similar symptoms to PD (e.g essential tremor ET), thus making it difficult to identify this disease in a timely manner. Unfortunately, dopamine agonist therapies have adverse side effects. Upon detection of PD, 80% of the dopaminergic neurons have already diminished. Deep Brain Stimulation (DBS) can significantly alleviate PD symptoms. This treatment reverses the expression profiles of both coding transcripts and microRNAs. Networks of microRNAs and targets can be generated using online tools, and expression data can be deposited in publicly available databases such as Gene Expression Omnibus (GEO) and Synapse. Additionally, transcript profiles in blood samples can be compared between rapidly and slowly progressing PD patients. Notably, mice exposed to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP) present with PD-like symptoms. Alternative splicing may also be detected in RNA samples from patients, and Gene Ontology (GO) pathways can be analyzed for molecular processes and biological pathways. Conclusion: Large-scale genomic studies of blood leukocyte transcript expression, particularly using the new technology of single cell sequencing, could significantly increase our understanding of the molecular mechanisms that underlie PD and perhaps also help guide RNA-based therapies (e.g using Cas/Crisper). 

Dr. Lilach Soreq and Prof. Dr. John Hardy

Guest Editors

deep brain stimulation
parkinson’s disease
Manuscript Submission Information

Manuscripts should be submitted via our online editorial system at by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 1900 USD. Submitted manuscripts should be well formatted in good English.

Back to top